

Special Issue

Focused Ultrasound and Cryoablation in Prostate Cancer: Recent Advances and Future Perspectives

Message from the Guest Editors

Prostate cancer (PCa) is the most commonly diagnosed cancer in men in developed countries. Over the past twenty years, there has been a trend towards the earlier diagnosis of PCa. Men are identified at an earlier stage with smaller unifocal or unilateral lesions that occupy only 5–10% of the prostate gland. Focal therapy (FT) could become a new treatment for men with localised PCa. It involves treating the tumor, while leaving the rest of the prostate and surrounding tissue intact. Most focal therapies are achieved with thermal ablative technologies. Increasing numbers of male patients, as well as urologists, are interested in this therapy. It could have the potential to cure PCA, while sparing patients from the side effects of radical treatment. The purpose of this Special Issue is to present the current developments and future perspectives of the two most commonly used types of FT, high-intensity focused ultrasound (HIFU) and cryoablation.

Guest Editors

Dr. Andrzej Lewicki

Department of Urology, Postgraduate Medical Education Centre, Professor Witold Orłowski Independent Public Clinical Hospital, 00-416 Warsaw, Poland

Prof. Dr. Jakub Dobruch

Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orłowski, 00-416 Warsaw, Poland

Deadline for manuscript submissions

closed (15 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/157683

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)